Halozyme Therapeutics (HALO) Gross Margin (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Gross Margin data on file, last reported at 78.97% in Q1 2026.

• On a quarterly basis, Gross Margin fell 276.0% year-over-year to 78.97% in Q1 2026; TTM through Mar 2026 was 82.79%, a 66.0% decrease from a year earlier, with the FY2025 full-year figure at 83.62%, down 68.0% from the prior year.
• Gross Margin for Q1 2026 stood at 78.97%, down from 82.56% in the prior quarter.
• Over the last five years, Gross Margin for HALO reached as high as 86.42% in Q1 2022 and fell as low as 74.62% in Q3 2023.
• Historically, Gross Margin has averaged 80.97% across 5 years, with a median of 81.73% in 2025.
• Across the five-year window, Gross Margin tumbled 811 bps in 2023 and jumped 862 bps in 2024, its largest moves.
• Year by year, Gross Margin stood at 76.79% in 2022, then advanced by 1 bps to 77.27% in 2023, then grew by 11 bps to 85.89% in 2024, then declined by 4 bps to 82.56% in 2025, then dropped by 4 bps to 78.97% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 78.97% in Q1 2026, 82.56% in Q4 2025, and 84.41% in Q3 2025.